nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—kidney cancer	0.221	0.549	CbGaD
Dabrafenib—BRAF—kidney cancer	0.153	0.381	CbGaD
Dabrafenib—RAF1—Sorafenib—kidney cancer	0.0875	0.237	CbGbCtD
Dabrafenib—BRAF—Sorafenib—kidney cancer	0.0732	0.198	CbGbCtD
Dabrafenib—ABCB1—kidney cancer	0.0283	0.0704	CbGaD
Dabrafenib—SLCO1B3—Paclitaxel—kidney cancer	0.0202	0.0546	CbGbCtD
Dabrafenib—SLCO1B1—Pazopanib—kidney cancer	0.018	0.0487	CbGbCtD
Dabrafenib—ABCG2—Pazopanib—kidney cancer	0.0143	0.0387	CbGbCtD
Dabrafenib—ABCG2—Dactinomycin—kidney cancer	0.0131	0.0354	CbGbCtD
Dabrafenib—ABCG2—Erlotinib—kidney cancer	0.0102	0.0276	CbGbCtD
Dabrafenib—ABCB1—Temsirolimus—kidney cancer	0.00982	0.0266	CbGbCtD
Dabrafenib—ABCG2—Paclitaxel—kidney cancer	0.00935	0.0253	CbGbCtD
Dabrafenib—CYP3A4—Everolimus—kidney cancer	0.00871	0.0236	CbGbCtD
Dabrafenib—ABCG2—Sorafenib—kidney cancer	0.0083	0.0224	CbGbCtD
Dabrafenib—ABCG2—Vincristine—kidney cancer	0.00806	0.0218	CbGbCtD
Dabrafenib—CYP2C8—Pazopanib—kidney cancer	0.00762	0.0206	CbGbCtD
Dabrafenib—ABCG2—Sunitinib—kidney cancer	0.00673	0.0182	CbGbCtD
Dabrafenib—CYP3A4—Temsirolimus—kidney cancer	0.00589	0.0159	CbGbCtD
Dabrafenib—CYP2C8—Erlotinib—kidney cancer	0.00544	0.0147	CbGbCtD
Dabrafenib—ABCB1—Pazopanib—kidney cancer	0.00516	0.014	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—kidney cancer	0.00504	0.0136	CbGbCtD
Dabrafenib—CYP2C8—Paclitaxel—kidney cancer	0.00498	0.0135	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—kidney cancer	0.00472	0.0128	CbGbCtD
Dabrafenib—CYP2C8—Sorafenib—kidney cancer	0.00442	0.012	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—kidney cancer	0.00373	0.0101	CbGbCtD
Dabrafenib—ABCB1—Erlotinib—kidney cancer	0.00368	0.00996	CbGbCtD
Dabrafenib—ABCB1—Paclitaxel—kidney cancer	0.00337	0.00911	CbGbCtD
Dabrafenib—CYP3A4—Pazopanib—kidney cancer	0.00309	0.00836	CbGbCtD
Dabrafenib—ABCB1—Sorafenib—kidney cancer	0.00299	0.00809	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—kidney cancer	0.00296	0.00799	CbGbCtD
Dabrafenib—ABCB1—Vincristine—kidney cancer	0.00291	0.00786	CbGbCtD
Dabrafenib—ABCB1—Sunitinib—kidney cancer	0.00243	0.00656	CbGbCtD
Dabrafenib—SLC22A8—nephron—kidney cancer	0.00227	0.105	CbGeAlD
Dabrafenib—CYP3A4—Erlotinib—kidney cancer	0.00221	0.00596	CbGbCtD
Dabrafenib—CYP3A4—Paclitaxel—kidney cancer	0.00202	0.00546	CbGbCtD
Dabrafenib—SLC22A8—urine—kidney cancer	0.00182	0.0841	CbGeAlD
Dabrafenib—ABCB1—Doxorubicin—kidney cancer	0.00182	0.00491	CbGbCtD
Dabrafenib—CYP3A4—Sorafenib—kidney cancer	0.00179	0.00485	CbGbCtD
Dabrafenib—CYP3A4—Vinblastine—kidney cancer	0.00177	0.00479	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—kidney cancer	0.00174	0.00471	CbGbCtD
Dabrafenib—CYP3A4—Sunitinib—kidney cancer	0.00145	0.00393	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—kidney cancer	0.00109	0.00294	CbGbCtD
Dabrafenib—SIK1—nephron tubule—kidney cancer	0.00106	0.0489	CbGeAlD
Dabrafenib—SIK1—renal system—kidney cancer	0.000964	0.0445	CbGeAlD
Dabrafenib—SIK1—kidney—kidney cancer	0.000932	0.043	CbGeAlD
Dabrafenib—SIK1—cortex of kidney—kidney cancer	0.000908	0.0419	CbGeAlD
Dabrafenib—CYP3A4—urine—kidney cancer	0.000904	0.0417	CbGeAlD
Dabrafenib—SIK1—gonad—kidney cancer	0.000865	0.0399	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—kidney cancer	0.000863	0.0398	CbGeAlD
Dabrafenib—RAF1—nephron tubule—kidney cancer	0.000844	0.0389	CbGeAlD
Dabrafenib—SLC22A6—nephron tubule—kidney cancer	0.00082	0.0378	CbGeAlD
Dabrafenib—RAF1—renal system—kidney cancer	0.000767	0.0354	CbGeAlD
Dabrafenib—RAF1—kidney—kidney cancer	0.000742	0.0342	CbGeAlD
Dabrafenib—RAF1—cortex of kidney—kidney cancer	0.000723	0.0333	CbGeAlD
Dabrafenib—SLC22A6—cortex of kidney—kidney cancer	0.000702	0.0324	CbGeAlD
Dabrafenib—RAF1—gonad—kidney cancer	0.000688	0.0317	CbGeAlD
Dabrafenib—RAF1—cardiac atrium—kidney cancer	0.000687	0.0317	CbGeAlD
Dabrafenib—SLCO1B1—renal system—kidney cancer	0.000574	0.0265	CbGeAlD
Dabrafenib—SLCO1B1—kidney—kidney cancer	0.000555	0.0256	CbGeAlD
Dabrafenib—SLC22A8—nephron tubule—kidney cancer	0.000491	0.0226	CbGeAlD
Dabrafenib—SLC22A8—renal system—kidney cancer	0.000446	0.0206	CbGeAlD
Dabrafenib—SLC22A8—kidney—kidney cancer	0.000431	0.0199	CbGeAlD
Dabrafenib—SLC22A8—cortex of kidney—kidney cancer	0.00042	0.0194	CbGeAlD
Dabrafenib—ABCG2—nephron tubule—kidney cancer	0.000349	0.0161	CbGeAlD
Dabrafenib—CYP2C8—renal system—kidney cancer	0.000326	0.0151	CbGeAlD
Dabrafenib—CYP2C8—kidney—kidney cancer	0.000316	0.0146	CbGeAlD
Dabrafenib—CYP3A4—renal system—kidney cancer	0.000221	0.0102	CbGeAlD
Dabrafenib—CYP3A4—kidney—kidney cancer	0.000214	0.00986	CbGeAlD
Dabrafenib—ABCB1—nephron tubule—kidney cancer	0.000172	0.00794	CbGeAlD
Dabrafenib—ABCB1—renal system—kidney cancer	0.000157	0.00722	CbGeAlD
Dabrafenib—ABCB1—kidney—kidney cancer	0.000151	0.00698	CbGeAlD
Dabrafenib—ABCB1—cortex of kidney—kidney cancer	0.000147	0.0068	CbGeAlD
Dabrafenib—ABCB1—gonad—kidney cancer	0.00014	0.00648	CbGeAlD
Dabrafenib—Dizziness—Everolimus—kidney cancer	4.71e-05	0.000359	CcSEcCtD
Dabrafenib—Muscle spasms—Paclitaxel—kidney cancer	4.71e-05	0.000359	CcSEcCtD
Dabrafenib—Abdominal pain—Sunitinib—kidney cancer	4.7e-05	0.000359	CcSEcCtD
Dabrafenib—Body temperature increased—Sunitinib—kidney cancer	4.7e-05	0.000359	CcSEcCtD
Dabrafenib—Diarrhoea—Erlotinib—kidney cancer	4.7e-05	0.000359	CcSEcCtD
Dabrafenib—Hypotension—Vincristine—kidney cancer	4.7e-05	0.000359	CcSEcCtD
Dabrafenib—Nervous system disorder—Gemcitabine—kidney cancer	4.68e-05	0.000357	CcSEcCtD
Dabrafenib—Thrombocytopenia—Gemcitabine—kidney cancer	4.67e-05	0.000356	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—kidney cancer	4.66e-05	0.000355	CcSEcCtD
Dabrafenib—Haemoglobin—Capecitabine—kidney cancer	4.64e-05	0.000354	CcSEcCtD
Dabrafenib—Skin disorder—Gemcitabine—kidney cancer	4.63e-05	0.000354	CcSEcCtD
Dabrafenib—Haemorrhage—Capecitabine—kidney cancer	4.61e-05	0.000352	CcSEcCtD
Dabrafenib—Vision blurred—Paclitaxel—kidney cancer	4.61e-05	0.000352	CcSEcCtD
Dabrafenib—Hyperhidrosis—Gemcitabine—kidney cancer	4.61e-05	0.000352	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—kidney cancer	4.6e-05	0.000351	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vincristine—kidney cancer	4.58e-05	0.00035	CcSEcCtD
Dabrafenib—Urinary tract disorder—Capecitabine—kidney cancer	4.56e-05	0.000348	CcSEcCtD
Dabrafenib—Hypersensitivity—Sorafenib—kidney cancer	4.55e-05	0.000347	CcSEcCtD
Dabrafenib—Insomnia—Vincristine—kidney cancer	4.55e-05	0.000347	CcSEcCtD
Dabrafenib—Oedema peripheral—Capecitabine—kidney cancer	4.55e-05	0.000347	CcSEcCtD
Dabrafenib—Vomiting—Vinblastine—kidney cancer	4.54e-05	0.000347	CcSEcCtD
Dabrafenib—Dizziness—Erlotinib—kidney cancer	4.54e-05	0.000347	CcSEcCtD
Dabrafenib—Connective tissue disorder—Capecitabine—kidney cancer	4.53e-05	0.000346	CcSEcCtD
Dabrafenib—Vomiting—Everolimus—kidney cancer	4.53e-05	0.000345	CcSEcCtD
Dabrafenib—Anaemia—Paclitaxel—kidney cancer	4.52e-05	0.000345	CcSEcCtD
Dabrafenib—Urethral disorder—Capecitabine—kidney cancer	4.52e-05	0.000345	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—kidney cancer	4.5e-05	0.000343	CcSEcCtD
Dabrafenib—Rash—Everolimus—kidney cancer	4.49e-05	0.000342	CcSEcCtD
Dabrafenib—Dermatitis—Everolimus—kidney cancer	4.48e-05	0.000342	CcSEcCtD
Dabrafenib—Headache—Vinblastine—kidney cancer	4.48e-05	0.000342	CcSEcCtD
Dabrafenib—Headache—Everolimus—kidney cancer	4.46e-05	0.00034	CcSEcCtD
Dabrafenib—Hypotension—Gemcitabine—kidney cancer	4.46e-05	0.00034	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—kidney cancer	4.45e-05	0.000339	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—kidney cancer	4.45e-05	0.000339	CcSEcCtD
Dabrafenib—Asthenia—Sorafenib—kidney cancer	4.43e-05	0.000338	CcSEcCtD
Dabrafenib—Leukopenia—Paclitaxel—kidney cancer	4.38e-05	0.000334	CcSEcCtD
Dabrafenib—Hypersensitivity—Sunitinib—kidney cancer	4.38e-05	0.000334	CcSEcCtD
Dabrafenib—Decreased appetite—Vincristine—kidney cancer	4.37e-05	0.000334	CcSEcCtD
Dabrafenib—Pruritus—Sorafenib—kidney cancer	4.37e-05	0.000334	CcSEcCtD
Dabrafenib—Vomiting—Erlotinib—kidney cancer	4.37e-05	0.000333	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	4.35e-05	0.000332	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vincristine—kidney cancer	4.34e-05	0.000331	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—kidney cancer	4.34e-05	0.000331	CcSEcCtD
Dabrafenib—Rash—Erlotinib—kidney cancer	4.33e-05	0.00033	CcSEcCtD
Dabrafenib—Dermatitis—Erlotinib—kidney cancer	4.33e-05	0.00033	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—kidney cancer	4.32e-05	0.000329	CcSEcCtD
Dabrafenib—Insomnia—Gemcitabine—kidney cancer	4.32e-05	0.000329	CcSEcCtD
Dabrafenib—Eye disorder—Capecitabine—kidney cancer	4.31e-05	0.000329	CcSEcCtD
Dabrafenib—Headache—Erlotinib—kidney cancer	4.3e-05	0.000328	CcSEcCtD
Dabrafenib—Constipation—Vincristine—kidney cancer	4.3e-05	0.000328	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—kidney cancer	4.3e-05	0.000328	CcSEcCtD
Dabrafenib—Cough—Paclitaxel—kidney cancer	4.27e-05	0.000326	CcSEcCtD
Dabrafenib—Asthenia—Sunitinib—kidney cancer	4.27e-05	0.000325	CcSEcCtD
Dabrafenib—Nausea—Vinblastine—kidney cancer	4.24e-05	0.000324	CcSEcCtD
Dabrafenib—Nausea—Everolimus—kidney cancer	4.23e-05	0.000323	CcSEcCtD
Dabrafenib—Diarrhoea—Sorafenib—kidney cancer	4.23e-05	0.000323	CcSEcCtD
Dabrafenib—Hypertension—Paclitaxel—kidney cancer	4.23e-05	0.000322	CcSEcCtD
Dabrafenib—Pruritus—Sunitinib—kidney cancer	4.21e-05	0.000321	CcSEcCtD
Dabrafenib—Angiopathy—Capecitabine—kidney cancer	4.19e-05	0.000319	CcSEcCtD
Dabrafenib—Immune system disorder—Capecitabine—kidney cancer	4.17e-05	0.000318	CcSEcCtD
Dabrafenib—Arthralgia—Paclitaxel—kidney cancer	4.17e-05	0.000318	CcSEcCtD
Dabrafenib—Myalgia—Paclitaxel—kidney cancer	4.17e-05	0.000318	CcSEcCtD
Dabrafenib—Mediastinal disorder—Capecitabine—kidney cancer	4.16e-05	0.000317	CcSEcCtD
Dabrafenib—Decreased appetite—Gemcitabine—kidney cancer	4.15e-05	0.000316	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—kidney cancer	4.15e-05	0.000316	CcSEcCtD
Dabrafenib—Chills—Capecitabine—kidney cancer	4.14e-05	0.000316	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	4.14e-05	0.000316	CcSEcCtD
Dabrafenib—Arrhythmia—Capecitabine—kidney cancer	4.12e-05	0.000314	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.12e-05	0.000314	CcSEcCtD
Dabrafenib—Fatigue—Gemcitabine—kidney cancer	4.11e-05	0.000314	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—kidney cancer	4.11e-05	0.000314	CcSEcCtD
Dabrafenib—Dizziness—Sorafenib—kidney cancer	4.09e-05	0.000312	CcSEcCtD
Dabrafenib—Constipation—Gemcitabine—kidney cancer	4.08e-05	0.000311	CcSEcCtD
Dabrafenib—Nausea—Erlotinib—kidney cancer	4.08e-05	0.000311	CcSEcCtD
Dabrafenib—Alopecia—Capecitabine—kidney cancer	4.08e-05	0.000311	CcSEcCtD
Dabrafenib—Dry mouth—Paclitaxel—kidney cancer	4.08e-05	0.000311	CcSEcCtD
Dabrafenib—Diarrhoea—Sunitinib—kidney cancer	4.07e-05	0.00031	CcSEcCtD
Dabrafenib—Mental disorder—Capecitabine—kidney cancer	4.04e-05	0.000308	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—kidney cancer	4.04e-05	0.000308	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—kidney cancer	4.03e-05	0.000307	CcSEcCtD
Dabrafenib—Erythema—Capecitabine—kidney cancer	4.02e-05	0.000306	CcSEcCtD
Dabrafenib—Malnutrition—Capecitabine—kidney cancer	4.02e-05	0.000306	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—kidney cancer	4e-05	0.000305	CcSEcCtD
Dabrafenib—Oedema—Paclitaxel—kidney cancer	3.99e-05	0.000305	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—kidney cancer	3.98e-05	0.000303	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—kidney cancer	3.98e-05	0.000303	CcSEcCtD
Dabrafenib—Infection—Paclitaxel—kidney cancer	3.97e-05	0.000303	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—kidney cancer	3.94e-05	0.000301	CcSEcCtD
Dabrafenib—Dizziness—Sunitinib—kidney cancer	3.93e-05	0.0003	CcSEcCtD
Dabrafenib—Vomiting—Sorafenib—kidney cancer	3.93e-05	0.0003	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—kidney cancer	3.93e-05	0.0003	CcSEcCtD
Dabrafenib—Nervous system disorder—Paclitaxel—kidney cancer	3.92e-05	0.000299	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—kidney cancer	3.91e-05	0.000298	CcSEcCtD
Dabrafenib—Thrombocytopenia—Paclitaxel—kidney cancer	3.91e-05	0.000298	CcSEcCtD
Dabrafenib—Rash—Sorafenib—kidney cancer	3.9e-05	0.000297	CcSEcCtD
Dabrafenib—Dermatitis—Sorafenib—kidney cancer	3.89e-05	0.000297	CcSEcCtD
Dabrafenib—Back pain—Capecitabine—kidney cancer	3.89e-05	0.000296	CcSEcCtD
Dabrafenib—Skin disorder—Paclitaxel—kidney cancer	3.88e-05	0.000296	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	3.87e-05	0.000295	CcSEcCtD
Dabrafenib—Headache—Sorafenib—kidney cancer	3.87e-05	0.000295	CcSEcCtD
Dabrafenib—Muscle spasms—Capecitabine—kidney cancer	3.86e-05	0.000295	CcSEcCtD
Dabrafenib—Hyperhidrosis—Paclitaxel—kidney cancer	3.86e-05	0.000295	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—kidney cancer	3.85e-05	0.000294	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—kidney cancer	3.84e-05	0.000293	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	3.79e-05	0.000289	CcSEcCtD
Dabrafenib—Vision blurred—Capecitabine—kidney cancer	3.79e-05	0.000289	CcSEcCtD
Dabrafenib—Vomiting—Sunitinib—kidney cancer	3.78e-05	0.000288	CcSEcCtD
Dabrafenib—Body temperature increased—Gemcitabine—kidney cancer	3.77e-05	0.000288	CcSEcCtD
Dabrafenib—Rash—Sunitinib—kidney cancer	3.75e-05	0.000286	CcSEcCtD
Dabrafenib—Dermatitis—Sunitinib—kidney cancer	3.75e-05	0.000286	CcSEcCtD
Dabrafenib—Hypotension—Paclitaxel—kidney cancer	3.73e-05	0.000285	CcSEcCtD
Dabrafenib—Headache—Sunitinib—kidney cancer	3.72e-05	0.000284	CcSEcCtD
Dabrafenib—Anaemia—Capecitabine—kidney cancer	3.71e-05	0.000283	CcSEcCtD
Dabrafenib—Hypersensitivity—Vincristine—kidney cancer	3.71e-05	0.000283	CcSEcCtD
Dabrafenib—Nausea—Sorafenib—kidney cancer	3.67e-05	0.00028	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—kidney cancer	3.64e-05	0.000278	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.64e-05	0.000278	CcSEcCtD
Dabrafenib—Insomnia—Paclitaxel—kidney cancer	3.61e-05	0.000276	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—kidney cancer	3.61e-05	0.000275	CcSEcCtD
Dabrafenib—Leukopenia—Capecitabine—kidney cancer	3.6e-05	0.000274	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—kidney cancer	3.58e-05	0.000273	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—kidney cancer	3.55e-05	0.000271	CcSEcCtD
Dabrafenib—Nausea—Sunitinib—kidney cancer	3.53e-05	0.000269	CcSEcCtD
Dabrafenib—Cough—Capecitabine—kidney cancer	3.5e-05	0.000267	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—kidney cancer	3.47e-05	0.000265	CcSEcCtD
Dabrafenib—Decreased appetite—Paclitaxel—kidney cancer	3.47e-05	0.000265	CcSEcCtD
Dabrafenib—Hypertension—Capecitabine—kidney cancer	3.47e-05	0.000265	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.45e-05	0.000263	CcSEcCtD
Dabrafenib—Fatigue—Paclitaxel—kidney cancer	3.44e-05	0.000263	CcSEcCtD
Dabrafenib—Diarrhoea—Vincristine—kidney cancer	3.44e-05	0.000263	CcSEcCtD
Dabrafenib—Asthenia—Gemcitabine—kidney cancer	3.42e-05	0.000261	CcSEcCtD
Dabrafenib—Arthralgia—Capecitabine—kidney cancer	3.42e-05	0.000261	CcSEcCtD
Dabrafenib—Myalgia—Capecitabine—kidney cancer	3.42e-05	0.000261	CcSEcCtD
Dabrafenib—Constipation—Paclitaxel—kidney cancer	3.42e-05	0.000261	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.4e-05	0.000259	CcSEcCtD
Dabrafenib—Pruritus—Gemcitabine—kidney cancer	3.38e-05	0.000258	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—kidney cancer	3.35e-05	0.000256	CcSEcCtD
Dabrafenib—Dry mouth—Capecitabine—kidney cancer	3.34e-05	0.000255	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—kidney cancer	3.34e-05	0.000255	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—kidney cancer	3.33e-05	0.000254	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—kidney cancer	3.31e-05	0.000253	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—kidney cancer	3.31e-05	0.000253	CcSEcCtD
Dabrafenib—Oedema—Capecitabine—kidney cancer	3.28e-05	0.00025	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Paclitaxel—kidney cancer	3.27e-05	0.000249	CcSEcCtD
Dabrafenib—Diarrhoea—Gemcitabine—kidney cancer	3.26e-05	0.000249	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—kidney cancer	3.26e-05	0.000248	CcSEcCtD
Dabrafenib—Infection—Capecitabine—kidney cancer	3.26e-05	0.000248	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—kidney cancer	3.23e-05	0.000246	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—kidney cancer	3.22e-05	0.000246	CcSEcCtD
Dabrafenib—Nervous system disorder—Capecitabine—kidney cancer	3.21e-05	0.000245	CcSEcCtD
Dabrafenib—Thrombocytopenia—Capecitabine—kidney cancer	3.21e-05	0.000245	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—kidney cancer	3.2e-05	0.000244	CcSEcCtD
Dabrafenib—Skin disorder—Capecitabine—kidney cancer	3.18e-05	0.000243	CcSEcCtD
Dabrafenib—Rash—Vincristine—kidney cancer	3.17e-05	0.000242	CcSEcCtD
Dabrafenib—Hyperhidrosis—Capecitabine—kidney cancer	3.17e-05	0.000242	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—kidney cancer	3.17e-05	0.000242	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—kidney cancer	3.16e-05	0.000241	CcSEcCtD
Dabrafenib—Body temperature increased—Paclitaxel—kidney cancer	3.16e-05	0.000241	CcSEcCtD
Dabrafenib—Abdominal pain—Paclitaxel—kidney cancer	3.16e-05	0.000241	CcSEcCtD
Dabrafenib—Headache—Vincristine—kidney cancer	3.15e-05	0.00024	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—kidney cancer	3.12e-05	0.000238	CcSEcCtD
Dabrafenib—Hypotension—Capecitabine—kidney cancer	3.06e-05	0.000234	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—kidney cancer	3.03e-05	0.000231	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—kidney cancer	3.01e-05	0.000229	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—kidney cancer	3.01e-05	0.000229	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—kidney cancer	2.99e-05	0.000228	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—kidney cancer	2.99e-05	0.000228	CcSEcCtD
Dabrafenib—Nausea—Vincristine—kidney cancer	2.99e-05	0.000228	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.99e-05	0.000228	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—kidney cancer	2.97e-05	0.000227	CcSEcCtD
Dabrafenib—Insomnia—Capecitabine—kidney cancer	2.96e-05	0.000226	CcSEcCtD
Dabrafenib—Hypersensitivity—Paclitaxel—kidney cancer	2.94e-05	0.000225	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—kidney cancer	2.94e-05	0.000224	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—kidney cancer	2.93e-05	0.000224	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—kidney cancer	2.92e-05	0.000223	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—kidney cancer	2.92e-05	0.000222	CcSEcCtD
Dabrafenib—Asthenia—Paclitaxel—kidney cancer	2.87e-05	0.000219	CcSEcCtD
Dabrafenib—Decreased appetite—Capecitabine—kidney cancer	2.85e-05	0.000217	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—kidney cancer	2.83e-05	0.000216	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Capecitabine—kidney cancer	2.83e-05	0.000216	CcSEcCtD
Dabrafenib—Fatigue—Capecitabine—kidney cancer	2.83e-05	0.000216	CcSEcCtD
Dabrafenib—Pruritus—Paclitaxel—kidney cancer	2.83e-05	0.000216	CcSEcCtD
Dabrafenib—Constipation—Capecitabine—kidney cancer	2.8e-05	0.000214	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—kidney cancer	2.78e-05	0.000212	CcSEcCtD
Dabrafenib—Diarrhoea—Paclitaxel—kidney cancer	2.73e-05	0.000209	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—kidney cancer	2.7e-05	0.000206	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—kidney cancer	2.69e-05	0.000205	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Capecitabine—kidney cancer	2.68e-05	0.000204	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—kidney cancer	2.68e-05	0.000204	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—kidney cancer	2.67e-05	0.000204	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—kidney cancer	2.66e-05	0.000203	CcSEcCtD
Dabrafenib—Dizziness—Paclitaxel—kidney cancer	2.64e-05	0.000202	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—kidney cancer	2.63e-05	0.000201	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—kidney cancer	2.61e-05	0.000199	CcSEcCtD
Dabrafenib—Abdominal pain—Capecitabine—kidney cancer	2.59e-05	0.000198	CcSEcCtD
Dabrafenib—Body temperature increased—Capecitabine—kidney cancer	2.59e-05	0.000198	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—kidney cancer	2.59e-05	0.000198	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—kidney cancer	2.59e-05	0.000198	CcSEcCtD
Dabrafenib—Vomiting—Paclitaxel—kidney cancer	2.54e-05	0.000194	CcSEcCtD
Dabrafenib—Rash—Paclitaxel—kidney cancer	2.52e-05	0.000192	CcSEcCtD
Dabrafenib—Dermatitis—Paclitaxel—kidney cancer	2.52e-05	0.000192	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—kidney cancer	2.5e-05	0.000191	CcSEcCtD
Dabrafenib—Headache—Paclitaxel—kidney cancer	2.5e-05	0.000191	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—kidney cancer	2.49e-05	0.00019	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—kidney cancer	2.44e-05	0.000186	CcSEcCtD
Dabrafenib—Hypersensitivity—Capecitabine—kidney cancer	2.42e-05	0.000184	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—kidney cancer	2.39e-05	0.000183	CcSEcCtD
Dabrafenib—Nausea—Paclitaxel—kidney cancer	2.37e-05	0.000181	CcSEcCtD
Dabrafenib—Asthenia—Capecitabine—kidney cancer	2.35e-05	0.000179	CcSEcCtD
Dabrafenib—Pruritus—Capecitabine—kidney cancer	2.32e-05	0.000177	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—kidney cancer	2.32e-05	0.000177	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—kidney cancer	2.26e-05	0.000172	CcSEcCtD
Dabrafenib—Diarrhoea—Capecitabine—kidney cancer	2.24e-05	0.000171	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—kidney cancer	2.24e-05	0.000171	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—kidney cancer	2.2e-05	0.000168	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—kidney cancer	2.2e-05	0.000168	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.19e-05	0.000167	CcSEcCtD
Dabrafenib—Dizziness—Capecitabine—kidney cancer	2.17e-05	0.000165	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—kidney cancer	2.16e-05	0.000164	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—kidney cancer	2.11e-05	0.000161	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—kidney cancer	2.1e-05	0.00016	CcSEcCtD
Dabrafenib—Vomiting—Capecitabine—kidney cancer	2.08e-05	0.000159	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—kidney cancer	2.07e-05	0.000158	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—kidney cancer	2.07e-05	0.000158	CcSEcCtD
Dabrafenib—Rash—Capecitabine—kidney cancer	2.07e-05	0.000158	CcSEcCtD
Dabrafenib—Dermatitis—Capecitabine—kidney cancer	2.06e-05	0.000158	CcSEcCtD
Dabrafenib—Headache—Capecitabine—kidney cancer	2.05e-05	0.000157	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—kidney cancer	2.05e-05	0.000157	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—kidney cancer	2.04e-05	0.000156	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—kidney cancer	1.97e-05	0.000151	CcSEcCtD
Dabrafenib—Nausea—Capecitabine—kidney cancer	1.95e-05	0.000149	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.93e-05	0.000147	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—kidney cancer	1.91e-05	0.000146	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—kidney cancer	1.84e-05	0.00014	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.82e-05	0.000139	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—kidney cancer	1.82e-05	0.000139	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—kidney cancer	1.81e-05	0.000138	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—kidney cancer	1.73e-05	0.000132	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—kidney cancer	1.67e-05	0.000127	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—kidney cancer	1.67e-05	0.000127	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—kidney cancer	1.56e-05	0.000119	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—kidney cancer	1.52e-05	0.000116	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—kidney cancer	1.49e-05	0.000114	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—kidney cancer	1.45e-05	0.00011	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—kidney cancer	1.4e-05	0.000107	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—kidney cancer	1.34e-05	0.000102	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—kidney cancer	1.33e-05	0.000102	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—kidney cancer	1.33e-05	0.000102	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—kidney cancer	1.32e-05	0.000101	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—kidney cancer	1.26e-05	9.58e-05	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—RELA—kidney cancer	5.33e-06	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—kidney cancer	5.29e-06	6.99e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC2A1—kidney cancer	5.29e-06	6.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—MTOR—kidney cancer	5.22e-06	6.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—kidney cancer	5.21e-06	6.89e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A3—kidney cancer	5.2e-06	6.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PGK1—kidney cancer	5.2e-06	6.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ANXA1—kidney cancer	5.19e-06	6.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC1—kidney cancer	5.19e-06	6.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSMD7—kidney cancer	5.19e-06	6.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PDHB—kidney cancer	5.19e-06	6.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—POMC—kidney cancer	5.17e-06	6.83e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—BCHE—kidney cancer	5.14e-06	6.78e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.13e-06	6.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1B—kidney cancer	5.11e-06	6.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LDHB—kidney cancer	5.1e-06	6.74e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA9—kidney cancer	5.08e-06	6.7e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC5A5—kidney cancer	5.07e-06	6.7e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—RAF1—kidney cancer	5.05e-06	6.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FLT1—kidney cancer	5.03e-06	6.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	4.96e-06	6.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1B—kidney cancer	4.9e-06	6.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC2A1—kidney cancer	4.9e-06	6.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CCBL1—kidney cancer	4.88e-06	6.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JUN—kidney cancer	4.86e-06	6.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	4.85e-06	6.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—kidney cancer	4.82e-06	6.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—kidney cancer	4.81e-06	6.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—kidney cancer	4.72e-06	6.23e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.7e-06	6.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTEN—kidney cancer	4.7e-06	6.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TSC2—kidney cancer	4.68e-06	6.18e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.67e-06	6.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PAK1—kidney cancer	4.66e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUNB—kidney cancer	4.66e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.59e-06	6.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MAPK3—kidney cancer	4.55e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—kidney cancer	4.51e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.48e-06	5.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MAPK3—kidney cancer	4.46e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.46e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA9—kidney cancer	4.42e-06	5.84e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—kidney cancer	4.41e-06	5.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HIF1A—kidney cancer	4.39e-06	5.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSC2—kidney cancer	4.38e-06	5.78e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	4.36e-06	5.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HIF1A—kidney cancer	4.33e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—RAF1—kidney cancer	4.33e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MAPK1—kidney cancer	4.33e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TSC2—kidney cancer	4.32e-06	5.71e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CRABP1—kidney cancer	4.32e-06	5.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—kidney cancer	4.31e-06	5.69e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—kidney cancer	4.28e-06	5.66e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—kidney cancer	4.27e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MAPK1—kidney cancer	4.24e-06	5.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTOR—kidney cancer	4.23e-06	5.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.23e-06	5.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPAT—kidney cancer	4.23e-06	5.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—kidney cancer	4.22e-06	5.57e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—kidney cancer	4.19e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—kidney cancer	4.19e-06	5.53e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—kidney cancer	4.18e-06	5.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—kidney cancer	4.13e-06	5.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	4.12e-06	5.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—kidney cancer	4.09e-06	5.4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—kidney cancer	4.09e-06	5.4e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—kidney cancer	4.06e-06	5.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK3—kidney cancer	4.02e-06	5.3e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ITPR2—kidney cancer	4.01e-06	5.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—kidney cancer	4.01e-06	5.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—kidney cancer	3.97e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APRT—kidney cancer	3.93e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FH—kidney cancer	3.93e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—kidney cancer	3.87e-06	5.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—kidney cancer	3.86e-06	5.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—kidney cancer	3.86e-06	5.1e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1A1—kidney cancer	3.85e-06	5.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK1—kidney cancer	3.82e-06	5.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—kidney cancer	3.82e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—kidney cancer	3.82e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF2—kidney cancer	3.81e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—kidney cancer	3.81e-06	5.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN2B—kidney cancer	3.8e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.79e-06	5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CRABP1—kidney cancer	3.76e-06	4.97e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—kidney cancer	3.76e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—kidney cancer	3.75e-06	4.95e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.7e-06	4.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPC3—kidney cancer	3.7e-06	4.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—kidney cancer	3.69e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CA—kidney cancer	3.68e-06	4.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—kidney cancer	3.68e-06	4.86e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.66e-06	4.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—kidney cancer	3.66e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ACHE—kidney cancer	3.66e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—kidney cancer	3.65e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—kidney cancer	3.61e-06	4.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA2—kidney cancer	3.6e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—kidney cancer	3.59e-06	4.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—kidney cancer	3.56e-06	4.71e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1A1—kidney cancer	3.56e-06	4.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALAD—kidney cancer	3.5e-06	4.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ITPR2—kidney cancer	3.5e-06	4.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—kidney cancer	3.47e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SCARB1—kidney cancer	3.46e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS1—kidney cancer	3.43e-06	4.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.42e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—kidney cancer	3.4e-06	4.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMD7—kidney cancer	3.36e-06	4.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.34e-06	4.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—kidney cancer	3.32e-06	4.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RELA—kidney cancer	3.23e-06	4.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—kidney cancer	3.21e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.2e-06	4.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PGK1—kidney cancer	3.2e-06	4.23e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—kidney cancer	3.19e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ACHE—kidney cancer	3.19e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—kidney cancer	3.19e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—kidney cancer	3.18e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—kidney cancer	3.18e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MTOR—kidney cancer	3.17e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—kidney cancer	3.16e-06	4.18e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.16e-06	4.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—kidney cancer	3.15e-06	4.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LDHB—kidney cancer	3.14e-06	4.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—kidney cancer	3.12e-06	4.12e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A1—kidney cancer	3.04e-06	4.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—kidney cancer	3.04e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—kidney cancer	3.03e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAF1—kidney cancer	3.03e-06	4.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC2—kidney cancer	3.03e-06	4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RELA—kidney cancer	3.02e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SCARB1—kidney cancer	3.02e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—kidney cancer	3e-06	3.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS1—kidney cancer	2.99e-06	3.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—kidney cancer	2.97e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK1—kidney cancer	2.97e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—kidney cancer	2.97e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—kidney cancer	2.96e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—kidney cancer	2.96e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.95e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMD7—kidney cancer	2.93e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—kidney cancer	2.93e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—kidney cancer	2.92e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—kidney cancer	2.91e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—kidney cancer	2.9e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—kidney cancer	2.9e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—kidney cancer	2.87e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—kidney cancer	2.83e-06	3.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—kidney cancer	2.81e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—kidney cancer	2.81e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—kidney cancer	2.78e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—kidney cancer	2.78e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—kidney cancer	2.75e-06	3.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—kidney cancer	2.74e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—kidney cancer	2.74e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA9—kidney cancer	2.72e-06	3.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—kidney cancer	2.72e-06	3.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—kidney cancer	2.67e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—kidney cancer	2.67e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—kidney cancer	2.65e-06	3.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—kidney cancer	2.65e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—kidney cancer	2.65e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—kidney cancer	2.65e-06	3.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—kidney cancer	2.63e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—kidney cancer	2.59e-06	3.43e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—kidney cancer	2.58e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.57e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—kidney cancer	2.56e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—kidney cancer	2.56e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—kidney cancer	2.54e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—kidney cancer	2.54e-06	3.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—kidney cancer	2.53e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.53e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—kidney cancer	2.51e-06	3.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK1—kidney cancer	2.44e-06	3.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—kidney cancer	2.4e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—kidney cancer	2.34e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—kidney cancer	2.33e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CRABP1—kidney cancer	2.32e-06	3.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—kidney cancer	2.31e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—kidney cancer	2.3e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—kidney cancer	2.29e-06	3.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK1—kidney cancer	2.23e-06	2.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—kidney cancer	2.21e-06	2.92e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—kidney cancer	2.21e-06	2.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—kidney cancer	2.19e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—kidney cancer	2.16e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ITPR2—kidney cancer	2.15e-06	2.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—kidney cancer	2.13e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—kidney cancer	2.12e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—kidney cancer	2.11e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—kidney cancer	2.1e-06	2.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—kidney cancer	2.1e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—kidney cancer	2.09e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RELA—kidney cancer	2.09e-06	2.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK1—kidney cancer	2.08e-06	2.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—kidney cancer	2.08e-06	2.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK1—kidney cancer	2.06e-06	2.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—kidney cancer	2.05e-06	2.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—kidney cancer	2.03e-06	2.68e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—kidney cancer	1.99e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—kidney cancer	1.96e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACHE—kidney cancer	1.96e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.96e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—kidney cancer	1.94e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—kidney cancer	1.93e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—kidney cancer	1.92e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—kidney cancer	1.92e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—kidney cancer	1.88e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.86e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—kidney cancer	1.85e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.84e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—kidney cancer	1.83e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—kidney cancer	1.83e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—kidney cancer	1.82e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.82e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—kidney cancer	1.8e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.8e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—kidney cancer	1.78e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—kidney cancer	1.77e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—kidney cancer	1.75e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—kidney cancer	1.71e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.69e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—kidney cancer	1.65e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.63e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—kidney cancer	1.6e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—kidney cancer	1.51e-06	2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—kidney cancer	1.47e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK1—kidney cancer	1.44e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—kidney cancer	1.44e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—kidney cancer	1.41e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—kidney cancer	1.36e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—kidney cancer	1.36e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—kidney cancer	1.31e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—kidney cancer	1.3e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.29e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.25e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—kidney cancer	1.25e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—kidney cancer	1.21e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.19e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—kidney cancer	1.15e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—kidney cancer	1.14e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—kidney cancer	9.98e-07	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—kidney cancer	8.84e-07	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—kidney cancer	8.08e-07	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—kidney cancer	7.05e-07	9.32e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—kidney cancer	7.04e-07	9.3e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—kidney cancer	6.15e-07	8.12e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.34e-07	5.73e-06	CbGpPWpGaD
